Drugs / Gastrodin
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07422142 | Mar → Sep 2026 overdue | delirium | Kunming Pharmaceuticals, Inc. | Not yet recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00297245 | Feb → May 2006 | cognitive disorder | Huazhong University of Science and Technology | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07283562 | Jan 2023 → Oct 2025 | sensorineural hearing loss disorder | The First Hospital of Hebei Medical University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gastrodin | “Gastrodin (4-\[hydroxymethyl\]phenyl-β-D-glucopyranoside), the primary active constituent of gastrodia elata” NCT00297245 ↗ |
| Known as | 4-\[hydroxymethyl\]phenyl-β-D-glucopyranoside | “Gastrodin (4-\[hydroxymethyl\]phenyl-β-D-glucopyranoside), the primary active constituent of gastrodia elata” NCT00297245 ↗ |
| Modality | Small molecule | — CHEMBL274739 ↗ |
| Route | Other | “gastrodin injected into selected acupoints” NCT07283562 ↗ |